When was Insitro founded?

Insitro was founded in 2018 and raised its 1st funding round 1 year after it was founded.

Where is Insitro located?

Insitro is headquartered in San Francisco, United States. It is registered at South San Francisco, California.

Who is the current CEO of Insitro?

Daphne Koller of Insitro. They have also founded 1 company.

How many employees does Insitro have?

As of Aug 31, 2026, the latest employee count at Insitro is 257.

Is Insitro a funded company?

Insitro is a funded company, having raised a total of $643M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jul 22, 2019.

How much is Insitro worth?

The latest valuation of Insitro is $***** as of Dec 31, 2025. This marks a decline of 7% from its peak valuation of $2.57B in Mar, 2021. This marks a decline of 7% from its peak valuation of $2.57B in Mar, 2021.

When was the latest funding round of Insitro?

Insitro's latest funding was a $***** Series C round on Mar 15, 2021, with participation from 13 investors. Its primary sector is Artificial Intelligence. In United States, the Artificial Intelligence sector has seen $322B in funding in 2026 to date.

Where does Insitro rank among its competitors?

Insitro ranks 4th amongst 666 active competitors, of which 248 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Strand Therapeutics, which secured $153M in May, 2025.

Who are the top competitors of Insitro?

Insitro's top competitors include Alnylam, Spark Therapeutics and Forge Biologics. Among them, Strand Therapeutics secured the most recent funding round in May, 2025.

Insitro - 2026 Company Profile, Team, Funding & Competitors

Insitro is a series C company based in San Francisco (United States), founded in 2018 by Daphne Koller. It operates as a Developer of machine learning platform for drug discovery and development. Insitro has raised $643M in funding from investors like Andreessen Horowitz, Google Ventures and Arch Venture Partners, with a current valuation of $*****. The company has 666 active competitors, including 248 funded and 134 that have exited. Its top competitors include companies like Alnylam, Spark Therapeutics and Forge Biologics.

Company Details

Developer of machine learning platform for drug discovery and development. The platform integrates cellular data with human clinical data to redefine disease. It aims to accelerate the development of new medicines. The platform identifies therapeutic insights and interventions across a wide spectrum of diseases. The company is building a pipeline of therapeutic programs in metabolism, oncology, and neuroscience.

Website: insitro.com
Social
Registered Address: South San Francisco, California

Key Metrics

Founded Year

2018

Location

San Francisco, United States

Stage

Series C

Total Funding

$643M in 3 rounds

Latest Funding Round

Series C, Mar 15, 2021, $*****

Post Money Valuation

$***** as on Dec 31, 2025

Investors

Andreessen Horowitz & 19 more

Ranked

4^th among 666 active competitors

Employee Count

257 as on Aug 31, 2026

Investment & Acquisitions

AION Labs & 1 more

Similar Companies

Alnylam & 3645 more

View Insitro's full profile

Insitro is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Insitro, Inc. CIN: 20201611433 , United States, Active	Jul 17, 2020	-	-	-
INSITRO INC. CIN: 824635443 , United States, Active	Dec 26, 999	-	284 (As on Dec 31, 2024)	-

Insitro has raised a total funding of $643M over 3 rounds. Its first funding round was on Jul 22, 2019. Its latest funding round was a Series C round on Mar 15, 2021 for $*****. 13 investors participated in its latest round. Insitro has 20 institutional investors.

Here is the list of recent funding rounds of Insitro:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 15, 2021	7796138	Series C	8017640	9692842	8921232	9401137
Mar 26, 2020	5281387	Series B	4618898	2628699	3676590	CPP Investments & 10 more
Jul 22, 2019	3227894	Series A	2501500	1199788	Arch Venture Partners & 4 more	Bezos Expeditions & 3 more

Access funding benchmarks and valuations. Sign up today!

View details of Insitro's funding rounds and investors

The founders of Insitro is Daphne Koller. Daphne Koller is the CEO of Insitro.

Here are the details of Insitro's key team members:

Daphne Koller: Founder & CEO of Insitro. They serve on the board of 1 company.

View details of Insitro's Founder profiles and Board Members

Insitro's employee count trend

Insitro has 257 employees as of Aug 26. Here is Insitro's employee count trend over the years:

Uncover Insitro's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Insitro include Alnylam, Spark Therapeutics and Forge Biologics. Here is the list of Top 10 competitors of Insitro, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	79/100
2nd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
3rd	Forge Biologics 2020, Columbus (United States), Acquired	Developer of gene therapeutic solutions for treating multiple diseases	$330M	RA Capital Management, Aisling Capital & 7 others	70/100
4th	Insitro 2018, San Francisco (United States), Series C	Developer of machine learning platform for drug discovery and development	$643M	ADS Ventures, Foresite Capital & 18 others	70/100
5th	DNAnexus 2009, Mountain View (United States), Series H	Provider of cloud-based genome informatics & data management platform	$473M	Google Ventures, TPG & 21 others	70/100
6th	Strand Therapeutics 2017, Cambridge (United States), Series B	Provider of platform to deliver mRNA therapeutics for multi functional treatments	$256M	Kinnevik, Playground Global & 19 others	69/100
7th	Passage Bio 2017, Philadelphia (United States), Public	Developer of gene therapies for CNS rare diseases	$226M	Access Biotechnology, Orbimed & 10 others	69/100
8th	Ultragenyx 2010, Novato (United States), Acquired	Developer of therapeutics for the treatment of rare and ultra-rare metabolic diseases	$135M	F-Prime Capital, Adage Capital Management ... & 10 others	69/100
9th	ElevateBio 2018, Cambridge (United States), Series D	Provider of transnational research for portfolio of cell and gene therapy	$1.25B	Matrix Capital Management, Invus & 16 others	68/100
10th	Krystal Biotech 2015, Pittsburgh (United States), Public	Developer of genetic medicines to treat rare diseases	$11.3M	Frazier Life Sciences, Danforth Advisors & 2 others	67/100